NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Yes, and my point is that while biopsy only patients were excluded from the trial, there were some number with significant residual tumor who were included, and they outlived their ECA counterparts. Why? Because DCVax works.

You fail to understand the numbers here.

In the patients with near total resection, where it was apples to apples, -L showed no benefit. In the patients who did not have near total resection is where -L showed the benefit. But it was in this latter group where all the partials and biopsies from the ECA were. Further, most all (including LL) expected -L to do relatively best in the patients with near total resection.

Look at it this way. Consider 3 groups of patients
1) Had near total resections
2) Had close to near total resections
3) Had partials and/or biopsies

Group 1 will be expected to live longer than group 2 and 2 longer than 3.

Because the -L trial had intent for near total resection it will be comprised almost entirely of 1 and 2, while the ECA has substantial group 3.

The reported MSD was group 1 for both arms. And no benefit. The "substial remaining disease" was 2 and 3. Thus that is where the effect of group 3 not being in -L wiould be seen.

One can reasonably argue the data is somewhat foggy here as the ECA reporting had limitations (the patient level data would be much better). Problem is, burden of proof is on NWBO.